Esperion has already received FDA approval (Feb 2020) for the first new oral cholesterol lowering drug in 20 years called Nexletol (bempedoic acid). Getting patient, doctor and insurance coverage traction, however, depends on whether the company can demonstrate meaningful reductions in major adverse cardiovascular events. On March 4th, 2023 at 10:30 AM ET, the market will get the proof they need as the company’s lead investigator presents the full data set of their large 14,000 patient CLEAR Cardiovascular Outcomes Trial at the American College of Cardiology (ACC) conference.

In fact, Esperion has already released top line data on December 7th, 2022. As the CEO explained, “With the announcement of these positive topline results, Bempedoic Acid (NEXLETOL®) becomes the first ATP-citrate lyase inhibitor to demonstrate significant and clinically meaningful outcomes results for patients in whom existing lipid lowering therapies fall short.” Click here for Press release

Listen to our discussion with management ahead of this important presentation to learn why the upcoming data reveal represents a game changing opportunity for Esperion shareholders.